Compare FICO & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FICO | ONC |
|---|---|---|
| Founded | 1956 | 2010 |
| Country | United States | Switzerland |
| Employees | N/A | 12000 |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.7B | 33.5B |
| IPO Year | 1995 | N/A |
| Metric | FICO | ONC |
|---|---|---|
| Price | $1,176.32 | $299.25 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 10 |
| Target Price | ★ $1,985.25 | $386.70 |
| AVG Volume (30 Days) | ★ 228.4K | 224.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 29.78 | N/A |
| EPS | ★ 6.61 | N/A |
| Revenue | ★ $1,032,475,000.00 | N/A |
| Revenue This Year | $27.68 | $759.19 |
| Revenue Next Year | $17.15 | $14.51 |
| P/E Ratio | ★ $194.48 | $614.06 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1,193.10 | $196.53 |
| 52 Week High | $2,217.60 | $385.22 |
| Indicator | FICO | ONC |
|---|---|---|
| Relative Strength Index (RSI) | 29.89 | 34.83 |
| Support Level | N/A | $292.79 |
| Resistance Level | $1,829.71 | $300.00 |
| Average True Range (ATR) | 64.25 | 9.26 |
| MACD | -4.22 | -4.32 |
| Stochastic Oscillator | 8.00 | 11.65 |
Founded in 1956, Fair Isaac Corporation is a leading applied analytics company. Fair Isaac is primarily known for its FICO credit scores, which is a widely used industry benchmark to determine the creditworthiness of an individual consumer. The firm's US-centric credit scores business accounts for most of the firm's revenue and profits and consists of business-to-business and business-to-consumer services. In addition to scores, Fair Isaac also sells software primarily to financial institutions for areas such as analytics, decision-making, customer workflows, and fraud.
BeOne Medicines Ltd is a holding company. Through its subsidiaries, it operates as an oncology-focused biopharmaceutical company engaged in the discovery and development of treatments for cancer. Its portfolio includes BRUKINSA (a Bruton's tyrosine kinase (BTK) inhibitor), sonrotoclax (a B-cell lymphoma 2 (BCL2) inhibitor, and a BTK chimeric degradation activation compound (BTK-CDAC). The company develops and commercializes wholly owned therapeutic assets targeting multiple mechanisms of action in oncology. The company operates in one segment: pharmaceutical products. It generates the majority of its revenue from the sale of its biopharmaceutical products.